Third Generation of ISCOM Technology

Isconova's adjuvant technology platform meet the need in modern vaccine development and antibody production of an industrially proven high performance novel adjuvant. The outstanding safety profile and exceptional efficacy are the key characteristics of the third generation ISCOM technology that Isconova now is proud to introduce.

1) ISCOM is a registered trademark of CSL Limited, Australia. For more information See Trademarks.